Transfusion requirements in patients with malignancy.
Aledort
L M
LM
Mount Sinai School of Medicine, New York, NY, USA.
Mohandas
K
K
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000740:Anemia / Q000209:etiology / Q000628:therapy*; D001803:Blood Transfusion / Q000191:economics*; D001943:Breast Neoplasms / Q000150:complications; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D003362:Cost-Benefit Analysis; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications*; D011994:Recombinant Proteins / Q000627:therapeutic use; D018570:Risk Assessment
D011994:Recombinant Proteins; D004921:Erythropoietin; D000068817:Epoetin Alfa